NetworkNewsAudio – PaxMedica Inc. (NASDAQ: PXMD) Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data
Related Press Release PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company, announced the completion of a type-B meeting with the FDA. During the live meeting, the company discussed the positive results of the recent data from its PAX-HAT-301 study of suramin in Stage One Human African Sleeping Sickness caused by Trypanosoma brucei rhodesiense, a rare and fatal parasitic disease if left untreated. To view the original press release, visit https://nnw.fm/CcN9z About PaxMedica Inc. PaxMedica is a forward-looking, clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (“APT”) aimed at addressing a range of challenging neurologic disorders. The company’s comprehensive portfolio encompasses a…